Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis

Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis

Objective: to evaluate the impact of tocilizumab (TCZ) therapy on the level of acute-phase indicators, autoantibodies, and immunoglobulins (Ig) G, M, and A after 2, 4, 8, 12, and 24 weeks as compared to the clinical efficacy of TCZ using DAS 28, SDAI, and CDAI scores and to reveal the immunological...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anastasia Sergeyevna Avdeyeva, E N Aleksandrova, E Yu Panasyuk, A A Novikov, M V Cherkasova, E L Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2012-06-01
Series:	Научно-практическая ревматология
Subjects:	das 28 cdai m a rheumatoid arthritis tocilizumab sdai erythrocyte sedimentation rate c-reactive protein igm/iga rheumatoid factors anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies immunoglobulins g
Online Access:	https://rsp.mediar-press.net/rsp/article/view/842
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-04-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-08-01)

Experience with tocilizumab in patients with rheumatoid arthritis (according to the data of the LORNET multicenter trial)
by: E Yu Panasyuk, et al.
Published: (2013-04-01)

IMPACT OF TOCILIZUMAB THERAPY ON STRUCTURAL JOINT DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS
by: Anastasia Sergeevna Avdeeva, et al.
Published: (2012-10-01)

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY
by: E N Aleksandrova, et al.
Published: (2011-06-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

ASSESSMENT OF RHEUMATOID ARTHRITIS ACTIVITY DURING PREGNANCY AND POSTPARTUM
by: E. V. Matyanova, et al.
Published: (2015-04-01)

EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
by: Anna Olegovna Pchelintseva, et al.
Published: (2014-02-01)

Bone destruction in rheumatoid arthritis: role of autoantibodies
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2013-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Elena Nikolayevna Aleksandrova, et al.
Published: (2012-02-01)

Comparative study of the clinical efficacy of the first domestic bioanalogue of tocilizumab based on the results of a randomized clinical trial of phase III
by: E. V. Akatova, et al.
Published: (2024-12-01)

Fibromyalgia as a Modifying Factor of Clinical Course of Rheumatoid Arthritis
by: Perebetyuk L.
Published: (2015-09-01)

Serum calprotectin levels: A measure of disease activity in rheumatoid arthritis
by: Pranshu Dhingra, et al.
Published: (2025-01-01)

The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis
by: Hui-Chun Yu, et al.
Published: (2019-01-01)

Rheumatoid factor and antibodies against cyclic citrullinated peptide in patients without rheumatoid arthritis
by: N. V. Bunchuk
Published: (2023-01-01)

Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
by: A. S. Avdeeva, et al.
Published: (2022-05-01)

SERUM FETUIN-A LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: E. V. Papichev, et al.
Published: (2019-09-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
by: Maria Sergeevna Voronina, et al.
Published: (2012-10-01)

CLINICAL CHARACTERISTICS OF THREE COHORTS OF PATIENTS WITH EARLY- AND LATE-ONSET RHEUMATOID ARTHRITIS (AT 50 YEARS OR OLDER). GENERALIZATION OF 40 YEARS’ EXPERIENCE
by: A. M. Satybaldyev, et al.
Published: (2020-04-01)

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS
by: E. L. Nasonov
Published: (2017-04-01)

The Role of IL-37 as an Anti-Inflammatory Biomarker in some Iraqi Rheumatoid Arthritis Patients and Its Correlation with DAS28
by: Sattar Brissm Hassan, et al.
Published: (2022-11-01)

IMPACT OF PREGNANCY ON THE ACTIVITY OF RHEUMATOID ARTHRITIS AND ITS THERAPY ACCORDING TO PROSPECTIVE FOLLOW-UP DATA
by: E. V. Matyanova, et al.
Published: (2015-09-01)

RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
by: V. V. Badokin, et al.
Published: (2011-06-01)

Clinical Characteristics, Comorbidities, and Sex-related Differences Among Smoking and Non-smoking Patients with Rheumatoid Arthritis: A Matched Case–control Study
by: Hanan M. Fathi, et al.
Published: (2025-04-01)

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis
by: N. V. Rebrova, et al.
Published: (2022-07-01)

Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry
by: Andreina Manfredi, et al.
Published: (2019-01-01)

Role of ultrasonic examination in assessment of the knee-joint state in patients with juvenile idiopathic arthritis
by: V. O. Roschina, et al.
Published: (2012-10-01)

THE CLINICAL AND DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN EARLY JUVENILEARTHRITIS
by: S O Salugina, et al.
Published: (2009-06-01)

Serum leptin level in rheumatoid arthritis and its relationship with disease activity
by: Zena M Al-Youzbaky, et al.
Published: (2023-02-01)

Triple positivity for autoantibodies in patients with rheumatoid arthritis is associated with a severe course of the disease but not with bone turnover markers
by: Tomasz Budlewski, et al.
Published: (2025-04-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
by: I. A. Guseva, et al.
Published: (2016-03-01)

Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease
by: E. L. Nasonov, et al.
Published: (2023-06-01)

Anti-cyclic citrullinated peptide antibodies – a role in rheumatoid arthritis and the possibility of seroconversion: A focus on abatacept
by: N. V. Chichasova
Published: (2017-03-01)

EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS
by: Yu. V. Muravyev
Published: (2018-07-01)

Relation of cytokine profile and antibody values to post-translational protein modifications in patients with rheumatoid arthritis (preliminary data)
by: D. А. Dibrov, et al.
Published: (2024-04-01)

Antibodies against post-translationally modified vimentin peptides in patients with rheumatoid arthritis
by: P. A. Kuznetsova, et al.
Published: (2017-09-01)

Seropositive juvenile rheumatoid arthritis: analysis of the spectrum of clinical manifestations and therapy according to a retrospective study
by: М. I. Kaleda, et al.
Published: (2021-02-01)

Clinical features of ACPA-negative and ACPA-positive variants of rheumatoid arthritis
by: D. A. Dibrov, et al.
Published: (2023-04-01)

ACCP-negative rheumatoid arthritis – clinical and immunological features
by: D. A. Dibrov
Published: (2022-07-01)

Association between Rheumatoid Arthritis Disease Activity and Comorbidities
by: Bahra Hussein Mohammed, et al.
Published: (2024-12-01)